Metraipolis › archive › dc_69b80d96db36

Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial — Europe PMC PMID:41582387

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41582387
DOI
10.2174/0118715303398749251027044323
License (as archived)
solo-consultazione
Archived
2026-11-07T05:40:15.021Z
SHA-256 of the archived text
75596b927e3a46ab7f0211abaf7b3626ecd6583c777092d27c83f6492f39d956
Stable URL of this page
https://metraipolis.com/documento/dc_69b80d96db36

How to cite

Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial — Europe PMC PMID:41582387 — Europe PMC (en), https://europepmc.org/article/MED/41582387 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_69b80d96db36 (Metraipolis archive dc_69b80d96db36, sha256 75596b927e3a46ab7f0211abaf7b3626ecd6583c777092d27c83f6492f39d956)
BibTeX
@misc{dc69b80d96db36,
  title = {Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial — Europe PMC PMID:41582387},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41582387},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_69b80d96db36; sha256 75596b927e3a46ab7f0211abaf7b3626ecd6583c777092d27c83f6492f39d956},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41582387. Agents can read the archived copy with the MCP tool read_document.